Ridge Biotechnologies (Ridge Bio), a company at the forefront of enzyme and targeted drug design aimed at advancing precision medicine, has emerged from stealth mode today, announcing an oversubscribed $25 million seed financing round. The funding was led by Sutter Hill Ventures (SHV), which also incubated the company, with additional participation from Overlap Holdings and other investors. Ridge Bio’s platform combines proprietary machine learning models with high-throughput, cell-free experimentation to accelerate the discovery and engineering of precision enzymes and therapeutic molecules. By integrating AI-driven prediction with rapid experimental validation, the company aims to significantly shorten the timeline and reduce the cost of developing next-generation biologics and targeted therapies. The platform enables the design of highly specific enzymes and drug candidates tailored to complex biological targets, with applications in treating diseases ranging from rare genetic disorders to cancer and neurodegenerative conditions. Ridge Bio’s approach is particularly focused on overcoming limitations in traditional drug discovery, where long development cycles and high failure rates remain persistent challenges. The seed funding will support the expansion of Ridge Bio’s technology platform, the growth of its scientific team, and the advancement of its lead programs into preclinical development. The company plans to leverage its AI-powered pipeline to identify and optimize novel therapeutic candidates with enhanced efficacy and safety profiles. Sutter Hill Ventures’ involvement underscores confidence in Ridge Bio’s innovative approach and its potential to transform biopharmaceutical discovery. The firm has a strong track record in backing early-stage life sciences startups with disruptive technologies. Ridge Bio’s emergence marks a significant step in the convergence of artificial intelligence and synthetic biology, highlighting how data-driven methods are reshaping the future of drug development. With its unique combination of machine learning and experimental throughput, the company is positioned to accelerate the delivery of precision medicines to patients in need.